REV-ERBα reduction is associated with clinicopathological features and prognosis in human gastric cancer

XIAOSHAN WANG¹, NANA WANG², XIANG WEI³, HAOYUAN YU¹ and ZHENGGUANG WANG¹

¹Department of General Surgery, The First Affiliated Hospital of Anhui Medical University; ²Laboratory of Pathophysiology, School of Life Sciences; ³Laboratory of Molecular Biology, Department of Biochemistry, Anhui Medical University, Hefei, Anhui 230032, P.R. China

Received October 22, 2017; Accepted April 13, 2018

DOI: 10.3892/ol.2018.8809

Abstract. Gastric cancer is a serious threat to human health. Nuclear receptor subfamily 1 group D member 1 (REV-ERBα) is a member of the nuclear hormone receptor family that regulates lipid metabolism, inflammatory responses and circadian rhythms. However, the role of REV-ERBα in the pathogenesis of human gastric cancer is unclear. The present study employed gastric cancer tissue samples from 74 patients and determined the association between REV-ERBα expression with clinicopathological variables and prognosis. Furthermore, the association between REV-ERBα and apoptosis in undifferentiated and moderately differentiated human gastric cancer cells was determined. It was identified that REV-ERBα expression was decreased in gastric cancer, which was positively associated with poor differentiation (P=0.009), T stage (P=0.001), Tumor-Node-Metastasis (TMN) stage (P=0.001) and lymph node metastasis (P=0.007). In the survival analysis, the 3- and 5-year survival times of patients were significantly associated with REV-ERBα expression (P=0.009 and P=0.002, respectively). Low REV-ERBα expression was associated with poor prognosis (P<0.05). Concurrently, cleaved caspase-3 expression was downregulated, whereas expression levels of Bcl-2 and the Bcl-2/Bax ratio were upregulated in gastric cancer tissues compared with normal tissues. REV-ERBα activator GSK4112 caused apoptosis in SGC-7901 and BGC-823 cell lines. REV-ERBα levels were decreased in human gastric cancer, which was associated with poor differentiation, TMN stages and poor prognosis. REV-ERBα is a potential biomarker for tumor development and prognosis, and a potential therapeutic target for gastric cancer.

Introduction

Gastric cancer is the most common cancer, with the fourth highest incidence rate of all gastric adenocarcinomas and >723,000 mortalities every year worldwide (1). Despite the decreased incidence and mortality rates due to the major improved diagnosis and treatment, the ≤5-year survival rate is <20% (1). This may be due to lack of understanding of the mechanisms underlying the development and prognosis of gastric cancer. Therefore, it is urgent to develop effective therapeutic approaches for gastric cancer.

Nuclear receptor subfamily 1 group D member 1 (REV-ERBα) belongs to the nuclear hormone receptor family (2), which is abundantly expressed in liver, adipose, muscle and brain tissue. REV-ERBα serves an important role in regulating lipid metabolism, inflammatory responses and circadian rhythm (2-4). Previous studies have demonstrated that REV-ERBα may modulate the proliferation and apoptosis of HER2+ breast cancer cells, which is associated with poor clinical outcomes and survival (5,6). However, to the best of our knowledge, there are no studies regarding the regulation of REV-ERBα in gastric cancer. It is also unknown whether REV-ERBα alterations are associated with the clinicopathological factors and prognosis of human gastric cancer. We hypothesize that the levels of REV-ERBα in gastric cancer are altered compared with normal tissues, and is associated with the clinicopathological features and prognosis of this disease. To examine this hypothesis, samples from patients who were diagnosed with gastric cancer were utilized, and the REV-ERBα gene and protein levels in normal and cancer tissues in those patients were compared. The associations between REV-ERBα expression with the Tumor-Node-Metastasis (TMN) stages and survival times were also analyzed in patients with gastric cancer. Finally, human gastric cancer cells were treated with REV-ERBα activator GSK4112 to determine its effects on apoptosis. Conclusively, the reduction of REV-ERBα was associated with clinical features and prognosis in gastric cancer, and REV-ERBα agonist resulted in apoptosis in gastric cancer cells.

Materials and methods

Patients and tissues collection. All samples were obtained from 74 patients with diagnosed gastric cancer who underwent
surgery (surgical resection) at The First Affiliated Hospital of Anhui Medical University in 2014, as previously described (7). The median age of the study population was 63.4 years (range, 33-84 years) and the sex distribution was 58 males and 16 females. The clinical characteristics are summarized in Table I. None of the patients had received any other therapies, including radiotherapy or chemotherapy prior to surgery. The hepatic, renal and bone marrow functions of all patients were normal, and the Eastern Cooperative Oncology Group Performance Status scores were between 0-2 (8). Patients with abnormal function rest results, and those who were pregnant or breast-feeding were excluded.

All patients provided written informed consent. The study protocol was approved by the Clinical Research Ethics Committee of Anhui Medical University (Hefei, China). All methods were performed in accordance with the human ethics guidelines in the clinical research project (9).

Cell culture. The human gastric cancer SGC-7901 [American Type Culture Collection (ATCC), Manassas, VA, USA] and BGC-823 (ATCC) cell lines and human normal gastric epithelial GES-1 (ATCC) cell line were employed to detect REV-ERBα expression. Cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing high glucose, 1 mmol/l L-glutamine, pyridoxine hydrochloride, 110 mg/l sodium pyruvate and bicarbonate. Additionally, 10% heat inactivated foetal calf serum (Clark Bioscience, Richmond, VA, USA), 100 U/ml penicillin and 100 µg/ml streptomycin were added to the DMEM. Cells were cultured at 37°C in a humidified atmosphere of 5% CO₂.

Immunohistochemistry. REV-ERBα expression in human gastric cancer and normal tissues (5 cm from the tumor site) was measured by immunohistochemistry as described previously (7). Immunohistochemistry was performed on 4-µm-thick sections from 10% formalin-fixed parrafin-embedded tissue specimens. Sections were deparaffinized with 100% xylene at 25°C for 10 min and removed xylene through a graded series (100, 85 and 70% ethanol) and were subjected to microwaving with 10 mm citrate buffer (pH=6.0) at 100°C for 5 min. Briefly, the sections were blocked with 3% hydrogen peroxide and 10% normal goat serum (Clark Bioscience) for 15 sec at 72°C. The qPCR primers for REV‑ERBα (rabbit; cat no. AB174309; 1:500 dilution; Abcam); cleaved caspase-3 (mouse; cat no. SC70497; 1:500 dilution; Santa Cruz Biotechnology, Inc., Dallas, TX, USA); B-cell lymphoma 2 (Bcl-2; mouse; cat no. SC23960; 1:500 dilution; Santa Cruz Biotechnology, Inc.); Bcl-2-associated X protein (Bax; mouse; cat no. SC23959; 1:500 dilution; Santa Cruz Biotechnology, Inc.); and β-actin (mouse; cat no. AB8226; 1:1,000 dilution; Abcam) overnight at 4°C, and then washed 3 times with TBST for 10 min each time. The membranes were incubated with the corresponding Goat anti-mouse horseradish peroxidase-conjugated secondary antibody (mouse; cat no. AP124P; 1:1,000 dilution; EMD Millipore, Billerica, MA, USA) or rabbit anti-Goat horseradish peroxidase-conjugated secondary antibody (rabbit; cat no. AP106P; 1:1,000 dilution; EMD Millipore) for 2 h at 20°C, and then washed 3 times with TBST again for 10 min each time. Finally, the detection of the molecules of interest was performed using enhanced chemiluminescence (Beyotime Institute of Biotechnology, Haimen, China). The bands were quantified to calculate relative protein expression levels using Quantity one software version 4.99.5.2.0 (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Reverse transcription quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted from human tissues and cells using TRIzol® (Life Technologies; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Total RNA was reverse transcribed by cDNA synthesis using a PrimeScript RT Reagent kit with gDNA Eraser (Perfect Real Time; Takara Bio, Inc., Otsu, Japan) at 37°C for 30 min and 85°C for 5 sec. qPCR was performed using a 7,900 Thermal Cycler (ABI, Applied Biosystems; Thermo Fisher Scientific, Inc.) with GoTaq® Green Master Mix (Promega Corporation, Madison, WI USA) at an initial denaturation at 95°C for 30 sec, followed by 40 cycles of denaturation for 5 sec at 95°C, annealing for 30 sec at 60°C and extension for 15 sec at 72°C. The qPCR primers for REV-ERBα were 5'-ACAGAAATCGAACTCTGCACTTCT-3' (forward)
and 5'-GGGAGGAGGACGGTATT-3' (reverse) (10). The primers for β-actin were 5' -CAT GTA CGT TGC TAT CCA GGC -3' (forward) and 5' -CTC CTT AT GTC ACG CAC GAT-3 (reverse). The cycle threshold (Cq) values were obtained in each sample. Relative levels of mRNA were determined using the 2^ΔΔCq method (10). β-actin was used as an internal gene for normalization.

**Morphological measurement of apoptosis.** The morphological changes associated with apoptosis were assayed using fluorescence microscopy following Hoechst33258 staining. The number of cells was counted in five random fields under a fluorescence microscope at a magnification of x200. Briefly, SGC-7901 and BGC-823 cells (3,500 cells/well) were fixed for 30 min at room temperature in 70% ethanol, followed by Hoechst33258 (10 µg/ml) staining for 2 min at 37°C and then visualization using the UV fluorescence microscope. Apoptotic cells were considered as cells exhibiting nuclear and cytoplasmic shrinkage, chromatin condensation and apoptotic bodies. A minimum of 400 cells were counted, and the percentage of apoptotic cells, or the apoptotic index, was calculated as described previously (11).

### Statistical analysis
Data are expressed as the mean ± standard deviation. Data analysis was performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). Comparison between different groups was performed using analysis of variance. The Student-Newman-Keuls test was the post-hoc test used following analysis of variance. The χ² test was utilized to analyze the associations between REV-ERBα expression levels and clinicopathological variables and survival time. A Kaplan-Meier test was utilized to describe survival curves and the log-rank test was used to analyze survival curves. P<0.05 was considered to indicate a statistically significant difference.

### Results
**REV-ERBα expression is decreased in human gastric cancer tissues.** The REV-ERBα expression levels in normal gastric and mucous gastric cancer tissues, and gastric cancer tissues with different TNM stages, were determined by immunohistochemistry. As demonstrated in Fig. 1A and B, REV-ERBα protein levels were decreased in gastric cancer tissues, which was associated with increased TNM stage. Additionally, REV-ERBα expression in mucous gastric cancer tissues

<table>
<thead>
<tr>
<th>Clinicopathological variables</th>
<th>Numbers of patients, n (n=74)</th>
<th>REV-ERBα expression level, n</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>58</td>
<td>35, 23</td>
<td>0.322</td>
</tr>
<tr>
<td>Female</td>
<td>16</td>
<td>8, 8</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60</td>
<td>23</td>
<td>16, 7</td>
<td>0.138</td>
</tr>
<tr>
<td>≥60</td>
<td>51</td>
<td>27, 24</td>
<td></td>
</tr>
<tr>
<td>Primary tumor site</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric cardia or fundus</td>
<td>36</td>
<td>22, 14</td>
<td>0.392</td>
</tr>
<tr>
<td>Gastric antrum or body</td>
<td>38</td>
<td>21, 17</td>
<td></td>
</tr>
<tr>
<td>Diameter of tumor, cm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;5</td>
<td>31</td>
<td>18, 13</td>
<td>0.995</td>
</tr>
<tr>
<td>≥5</td>
<td>43</td>
<td>25, 18</td>
<td></td>
</tr>
<tr>
<td>Level of differentiation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>22</td>
<td>8, 14</td>
<td>0.009</td>
</tr>
<tr>
<td>Poor</td>
<td>52</td>
<td>37, 15</td>
<td></td>
</tr>
<tr>
<td>T stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1-T2</td>
<td>21</td>
<td>5, 16</td>
<td>0.001</td>
</tr>
<tr>
<td>T3-T4</td>
<td>53</td>
<td>39, 14</td>
<td></td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I-II</td>
<td>18</td>
<td>4, 14</td>
<td>0.001</td>
</tr>
<tr>
<td>III-IV</td>
<td>56</td>
<td>40, 16</td>
<td></td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Present</td>
<td>58</td>
<td>41, 17</td>
<td>0.007</td>
</tr>
<tr>
<td>Absent</td>
<td>16</td>
<td>5, 11</td>
<td></td>
</tr>
</tbody>
</table>

TNM, Tumor-Node-Metastasis; REV-ERBα, nuclear receptor subfamily 1 group D member 1.
was also decreased compared with normal gastric tissues. Furthermore, the REV-ERBα expression in normal gastric and gastric cancer tissues was confirmed by western blot analysis (Fig. 1C and D). The mRNA levels of REV-ERBα were also measured by RT-qPCR (Fig. 1E). It was identified that the levels of REV-ERBα mRNA were also decreased in gastric cancer tissues, which was associated with incremental TNM stage. These results suggest that REV-ERBα levels are decreased significantly in gastric cancer tissues with higher TNM stages.

Association between REV-ERBα expression and clinicopathological factors in gastric cancer. The association between the REV-ERBα expression and clinicopathological factors was analyzed using immunohistochemistry data (Table I). A low expression of REV-ERBα was significantly associated with poor differentiation (P=0.009), T stage (P=0.001), TMN stage (P=0.001) and lymph node metastasis (P=0.007). The results indicated that REV-ERBα level is associated with the progression of gastric cancer.

Association between REV-ERBα expression and survival time of patients with gastric cancer. The different survival times of patients with low and high REV-ERBα expression levels are summarized in Table II. The 3- and 5-year survival times of patients were significantly associated with REV-ERBα expression (P=0.009 and P=0.002, respectively). The patients with low REV-ERBα expression exhibited poor prognosis (P<0.05) compared with patients with high REV-ERBα expression (Fig. 2).

Cleaved caspase-3 expression is downregulated, whereas the Bcl-2 expression and Bcl-2/Bax are upregulated, in gastric cancer tissues. To determine whether REV-ERBα was associated with the expression of cleaved caspase-3, Bcl-2 and Bax, western blot analysis was employed to detect the levels of these proteins. As indicated in Fig. 3A and B, the expression levels of cleaved caspase-3 were downregulated in gastric cancer tissues, which was associated with enhanced TNM stage. The Bcl-2 expression levels were upregulated in gastric cancer tissues, which were also associated with enhanced TNM stage. Additionally, the ratio of Bcl-2 to Bax, according to the densitometry of the western blot analysis bands (Fig. 3C), was increased in gastric cancer tissues compared with normal
gastric tissues. Therefore, these results suggest that the level of REV-ERBα is decreased in human gastric cancer, which is associated with decreased levels of apoptosis.

**REV-ERBα expression is decreased in human gastric cancer cells, and activation of REV-ERBα causes apoptosis in gastric cancer cells.** To additionally investigate the REV-ERBα expression in gastric cancer, GES-1, SGC-7901 and BGC-823 cell lines were employed to determine the expression level of REV-ERBα (Fig. 4A and B). The REV-ERBα expression levels were significantly decreased in SGC-7901 (moderately differentiated) and BGC-823 (undifferentiated) compared with the GES-1 cell line. The mRNA levels of REV-ERBα were also decreased in SGC-7901 and BGC-823 cells compared with the GES-1 cell line (Fig. 4C). Furthermore, SGC-7901 and BGC-823 cells were treated with the REV-ERBα activator GSK4112 (20 and 40 µM; MedChemExpress, Monmouth Junction, NJ, USA), and it was identified that GSK4112 treatment for 48 h at 37°C caused an increase in apoptosis in a dose-dependent manner (Fig. 5). Therefore, these results suggest that REV-ERBα activation induces apoptosis in human gastric cancer cells.

**Discussion**

REV-ERBs were originally regarded as orphan receptors to regulate gene transcription in response to multifarious environmental stimuli (12). The members of REV-ERB family, including REV-ERBα and REV-ERBβ, exhibit abundant and overlapping expression in adipose, muscle, brain and liver tissues (13). However, REV-ERBα is broadly expressed at the similar level in a number of different tissues, whereas REV-ERBβ is highly expressed in parts of the brain, including the pineal gland and prefrontal cortex, thyroid, uterus and pituitary (12).

REV-ERBα modulates the circadian rhythm by directly activating the expression of key circadian clock genes, including Clock circadian regulator, Brain and muscle ANRT-like 1,
Cryptochrome and Period (14-17). Epidemiological data indicate that disruption of the circadian clock is associated with an increased risk of development of breast cancer (18,19). Dysregulation of the circadian clock genes may have complex effects on energy homeostasis, potentially resulting in metabolic disorders including cancer (20,21). The present study identified that REV-ERBα expression was significantly decreased in human gastric cancer tissues, which was associated with different clinicopathological stages. This was in agreement with the results that the levels of REV-ERBα were additionally decreased in undifferentiated BGC-823 cells compared with moderately differentiated SGC-7901 cells. These data suggest the possibility of REV-ERBα as a biomarker of gastric cancer.

It has also been demonstrated that the REV-ERBα expression leading to apoptosis was affected by circadian rhythms (22). REV-ERBα controls the circadian clock genes and regulates Early growth response 1 expression, causing extensive expression of Tumor protein p73 (p73) (23). p73 activates the transcription of Bax and Bcl-2, causing the release of cytochrome c from the mitochondria (24). Apoptosome assembly, and the eventual cleavage and activation of transducer caspase-9, in turn cleaves and activates executioner caspase-3. Hence, the circadian clock has a regulating role in the expression of apoptosis factors (Caspase-3, Bcl-2 and Bax) and the activation of the apoptosis pathway (24). The present study identified that REV-ERBα expression was decreased in human gastric cancer, and that this decrease may protect against apoptosis by decreasing the levels of cleaved caspase-3 and increasing Bcl-2 levels. However, one limitation of the present study is that there were only 74 patients included. A larger human cohort is required to confirm these results. It was also unknown how REV-ERBα regulates the
apoptosis pathway and expression of apoptosis-associated factors, including cleaved caspase-3, Bcl-2 and Bax, in gastric cancer.

It has been demonstrated previously that REV-ERBα regulates lipid metabolism during proliferation and apoptosis (2,25,26). The preliminary data from the present study suggested that REV-ERBα decreased glycolysis levels in gastric cancer cells (data not shown). Nevertheless, it is unclear whether a REV-ERBα-mediated decrease of glycolysis is beneficial for therapy in gastric cancer.

In summary, the present study employed immunohistochemistry, western blot analysis and RT-qPCR methods, and identified that REV-ERBα expression was decreased in human gastric cancer tissues. The data indicated that REV-ERBα expression was significantly associated with poor differentiation, T stage, TNM stage and lymph node metastasis in human gastric cancer. Additionally, the survival time of patients was significantly associated with REV-ERBα expression, suggesting that REV-ERBα may be an independent prognosis factor in gastric cancer. Furthermore, REV-ERBα activation induced apoptosis in human gastric cancer cells. Therefore, REV-ERBα is a potential biomarker for tumor development and prognosis, and a potential therapeutic target for gastric cancer.

Acknowledgements
Not applicable.

Funding
The present study was funded by the Natural Science Foundation of Anhui Province (grant no. 1608085MH182).

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors’ contributions
XSW and ZW designed the study. NW performed the immunohistochemistry to determine the expression of REV-ERBα. XSW and XW conducted the western blot analysis. XW also performed the cell proliferation and morphological measurements of apoptosis. HY performed RT-qPCR to detect the expression of REV-ERBα. XSW drafted the manuscript.

Ethics approval and consent to participate
The study protocol was approved by the Clinical Research Ethics Committee of Anhui Medical University (Hefei, China). Informed consent was obtained from all individual participants included in the study.

Consent for publication
Written informed consent was obtained from all patients for the publication of their data.

Competing interests
The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.